Stay updated on Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial

Sign up to get notified when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:07:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the dose of interleukin-2 (IL-2) given in combination with pembrolizumab for the therapy of metastatic kidney cancer. This change may impact the treatment plan and dosing schedule for patients participating in the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:50.000Z thumbnail image
  7. Check
    13 days ago
    Change Detected
    Summary
    The change on the webpage represents an update in the Estimated Study Completion Date, which is now estimated to be in 2024-06. This change may indicate a shift in the timeline for the completion of the study on interleukin-2 and pembrolizumab for metastatic kidney cancer.
    Difference
    0.0%
    Check dated 2024-06-03T12:42:54.000Z thumbnail image
  8. Check
    15 days ago
    Change Detected
    Summary
    The value 02 22 04 02 20 02 22 02 has recently changed to 05 31 06 05 15 (Estimated) 05 31 05. This change likely represents an update or modification in the study completion date for the clinical trial on Coordinated High Dose Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer.
    Difference
    0.8%
    Check dated 2024-06-01T11:21:34.000Z thumbnail image
  9. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' now includes specific inclusion criteria for metastatic kidney cancer and other detailed requirements for trial entry.
    Difference
    48%
    Check dated 2024-05-22T21:16:54.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:40:43.000Z thumbnail image

Stay in the know with updates to Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.